Document:

Amendment Number 3 to Rights Agreement

 Exhibit 4.3 
 AMENDMENT NO. 3 TO RIGHTS AGREEMENT 
 This
Amendment No. 3 to Rights Agreement (this “Amendment”), which is effective March 31, 2010, is by and between MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.) (the “Company”), and American Stock
Transfer & Trust Company, LLC (the “Rights Agent”). Capitalized terms used in this Amendment but not otherwise defined herein shall have the meanings ascribed to such terms in the Rights Agreement (as defined in the
recitals below). 
 WHEREAS, the Company and the Rights Agent previously entered into that certain Rights Agreement dated
February 22, 2000, as amended as of January 17, 2007 and March 17, 2010 (as so amended, the “Rights Agreement”) to provide for, among other things, certain preferred share purchase rights of the Company’s
stockholders; and 
 WHEREAS, pursuant to Section 27 of the Rights Agreement, the Board of Directors of the Company
(the “Board”) is permitted to amend the Rights Agreement; and 
 WHEREAS, the Company, Calais
Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Cequent Pharmaceuticals, Inc., a Delaware corporation (“Cequent”), are entering into an Agreement and Plan of
Merger, dated as of March 31, 2010 (as it may be amended from time to time, the “Merger Agreement”), with respect to the acquisition of Cequent by the Company; and 
 WHEREAS, the Board has approved and declared advisable the Merger (as defined in the Merger Agreement), the Merger Agreement and the
transactions contemplated by the Merger Agreement, and has declared that it is in the best interests of its stockholders that the Company enter into the Merger Agreement and consummate the transactions contemplated by the Merger Agreement on the
terms and subject to the conditions set forth in the Merger Agreement; and 
 WHEREAS, the Board has determined that it
is in the best interests of the Company and its stockholders, and is consistent with the objectives of the Board in adopting the Rights Agreement, to amend the Rights Agreement to exempt the Merger, the Merger Agreement and all of the transactions
contemplated by the Merger Agreement, from the application of the Rights Agreement; and 
 WHEREAS, pursuant to a
resolution duly adopted, the Board authorized and directed the execution and delivery of this Amendment; 
 NOW,
THEREFORE, in consideration of the rights and obligations contained herein, and for other good and valuable consideration, the adequacy of which is hereby acknowledged, the parties agree as follows: 
  

	 	1.	Amendments to Section 1. 

 (a) Section 1(a) of the Rights Agreement is hereby amended by adding the following

 
sentence to the end of Section 1(a): 
 “Notwithstanding the
foregoing, no Person shall be deemed to be an Acquiring Person by reason of: (1) the approval, execution or delivery of the Merger Agreement or the Voting Agreements (as defined in the Merger Agreement); (2) the announcement or
consummation of the Merger (as defined in the Merger Agreement); or (3) the consummation of any other transactions specifically contemplated by the Merger Agreement.” 
 (b) Section 1 of the Rights Agreement is hereby amended by adding the following definition in alphabetical order: 
 “Merger Agreement” shall mean that certain Agreement and Plan of Merger among the Company, Calais Acquisition Corp., a
Delaware corporation and wholly-owned subsidiary of the Company, and Cequent Pharmaceuticals, Inc., a Delaware corporation, dated as of March 31, 2010, as it may be amended from time to time.” 
 3. Amendment to Section 15. Section 15 of the Rights Agreement is hereby amended by adding the following sentence at the
end thereof: 
 “Nothing in this Agreement shall be construed to give any holder of Rights or any other Person any legal or
equitable right, remedy or claim under this Agreement in connection with any transactions contemplated by the Merger Agreement.” 
 4. New Section 34. The Rights Agreement is hereby amended by adding a new Section 34 to the end thereof as follows: 
 “Section 34. Merger Agreement. Notwithstanding anything in this Agreement that might otherwise be deemed to the contrary, no Distribution Date and no event described in Section 13,
shall occur, or be deemed to occur, and no Rights shall be exercisable under this Agreement, by reason of: (1) the approval, execution or delivery of the Merger Agreement or the Voting Agreements (as defined in the Merger Agreement);
(2) the announcement or consummation of the Merger; or (3) the consummation of any other transactions specifically contemplated by the Merger Agreement.” 
 5. Full Force and Effect. Except as expressly amended by this Amendment, the Rights Agreement shall remain in full force and effect, and all references to the Rights Agreement from and after such
time shall be deemed to be references to the Rights Agreement as amended hereby. In the event of any conflict, inconsistency or incongruity between any provision of this Amendment and any provision of the Rights Agreement, the provisions of this
Amendment shall govern and control for purposes of the subject matter of this Amendment only. This Amendment shall be construed in accordance with and as a part of the Rights Agreement, and all terms, conditions, representations, warranties,
covenants and agreements set forth in the Rights Agreement and each other instrument or agreement referred to therein, except as herein amended, are hereby ratified and confirmed. 

 6. Effectiveness. This Amendment shall be deemed effective as of the date first
written above as if executed on such date. 
 7. Governing Law. This Amendment shall be deemed to be a contract made
under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of such state applicable to contracts to be made and performed entirely within such state. 
 8. Counterparts. This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be
deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 
 9.
Severability. The parties intend that this Amendment be enforced and interpreted as written. If, however, any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be
invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect and shall in no way be affected, impaired or invalidated. 
 10. Descriptive Headings. Descriptive headings of the several sections, subsections and provisions of this Amendment are inserted for
convenience of reference only and shall not control or affect the meaning, interpretation or construction of any of the terms or provisions hereof. 
 11. Exhibits to the Rights Agreement. Exhibit B (“Form of Right Certificate”) and Exhibit C (“Summary of Rights to Purchase Preferred Shares”) to the Rights
Agreement are hereby deemed to be amended in a manner consistent with this Amendment. 
 [remainder of page intentionally left
blank; signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
executed by their respective officers thereunto duly authorized as of this 31st day of March, 2010. 
  

			
	MDRNA, INC.
		
	By:	 	 /s/ Peter S. Garcia

	Name:	 	Peter S. Garcia
	Title:	 	Chief Financial Officer
	
	 AMERICAN STOCK TRANSFER
 & TRUST COMPANY, LLC

		
	By:	 	 /s/ Paula Caroppoli

	Name:	 	Paula Caroppoli
	Title:	 	Vice PresidentForm of Lock-Up Agreement

 Exhibit 10.1 
 Lock-Up Agreement 
             , 2010 
 MDRNA, Inc. 
 3830 Monte Villa Parkway 
 Bothell, WA 98021

 Ladies and Gentlemen: 
 The undersigned understands that MDRNA, Inc. (the “MDRNA”) has entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among MDRNA, Marseilles Acquisition Corp., a wholly-owned
subsidiary of MDRNA (“Merger Sub”), and Cequent Pharmaceuticals, Inc. (“Cequent”), providing for the merger of Merger Sub with and into Cequent, with Cequent surviving as a wholly-owned subsidiary of MDRNA (the
“Merger”). In connection with the Merger, MDRNA will issue shares (the “Consideration Shares”) of its common stock, par value $0.006 per share (“Common Stock”), to the securityholders of Cequent,
including the undersigned. For the avoidance of doubt, the term “Consideration Shares” shall also include all of the shares of Common Stock issuable by MDRNA upon exercise of options to purchase Common Stock that MDRNA issues to the
holders of Company Options, which Company Options will be assumed by MDRNA in connection with the Merger. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Merger Agreement. 
 To induce MDRNA to consummate the Merger and to issue the Consideration Shares, the undersigned hereby agrees that, without the prior
written consent of MDRNA, it will not, during the period commencing on the effective date of the Merger and ending on the earlier of (A) one hundred and eighty (180) days thereafter or (B) thirty (30) days following the closing
of an equity financing by MDRNA for the issuance of shares of equity or securities convertible into or exchangeable or exercisable for shares of equity of MDRNA (an “Equity Financing”) which, when added together with all other
Equity Financings from and after the date of execution of the Merger Agreement, results in aggregate gross proceeds to MDRNA of at least $10 million (the “Lock-Up Period”), (1) offer, pledge, sell, contract to sell, grant,
lend, or otherwise transfer or dispose of, directly or indirectly, any Consideration Shares or any securities convertible into or exercisable or exchangeable for Consideration Shares, or (2) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Consideration Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Consideration Shares or
such other securities, in cash or otherwise. 
 Notwithstanding the foregoing, the undersigned may transfer Consideration Shares
without the prior consent of MDRNA in connection with (a) transfers of Consideration Shares or any security convertible into Consideration Shares as a bona fide gift, by will or intestacy or to a family member or trust for the benefit of a
family member; provided that in the case of any transfer or distribution pursuant to clause (a), (i) each donee or distributee shall sign and deliver a lock-up letter substantially in the form of this letter agreement and
(ii) no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), reporting a reduction in beneficial ownership by the undersigned of Shares, shall be required or shall be
voluntarily made during the Lock-up Period, (b) transfer of Consideration Shares to a charity or educational institution, (c) if the undersigned is a corporation, partnership, limited liability company or other business entity, any
transfers of Consideration Shares to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case may be, if, in any such case, such transfer is not for value or (d) if the undersigned is a
corporation, partnership, limited liability company or other business entity, any transfer of Consideration Shares made by the undersigned (i) in connection with the sale or other bona fide transfer in a single transaction of all or
substantially all of the undersigned’s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the undersigned’s assets, in any such case not
undertaken for the purpose of avoiding the restrictions imposed by this agreement, (ii) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate of the undersigned and
such transfer is not for value, or (iii) to the beneficial owners thereof so long as such transfer is on a pro rata basis and such transfer is not for value. 

 In addition, the undersigned agrees and consents to the entry of stop transfer instructions
with MDRNA’s transfer agent and registrar against the transfer of the undersigned’s Consideration Shares except in compliance with this agreement. 
 The undersigned shall not be subject to any of the foregoing restrictions in this agreement unless and until MDRNA has confirmed in writing to the undersigned that all officers and directors of MDRNA have
executed similar agreements. 
 In the event a certain percentage of the securities held by the officers and/or directors of
MDRNA are released from the restrictions set forth in agreements similar to this agreement prior to the end of the Lock-Up Period, the same percentage of the securities held by the undersigned shall be immediately and fully released from any
remaining restrictions under this agreement concurrently therewith. In the event that the undersigned is released early pursuant to the terms of this paragraph, MDRNA shall notify the undersigned concurrently with notification to such other released
party. 
 The undersigned understands that MDRNA is relying upon this agreement in entering into and consummating the Merger.
The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns. 
  

			
	Very truly yours,	 	
	
	  

	Name:	 	
	  
 Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]